TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say

Shortly after the launch of TriLipix, Abbott is seeing patients switch from its established fenofibrate TriCor to the next-generation drug- a welcoming sign for the firm, given that TriCor is expected to face generics in 2011